Abstract:The increasing focus on patient centricity in the pharmaceutical industry over the past decade and the changing healthcare landscape, driven by factors such as increased access to information, social media, and evolving patient demands, has necessitated a shift toward greater connectivity and understanding of patients' unique treatment needs. One pharmaceutical technology that has supported these efforts is long acting injectables (LAIs), which lower the administration frequency for the patient's provided convenience, better compliance, and hence better therapeutical treatment for the patients. Furthermore, patients with conditions like the human immunodeficiency virus and schizophrenia have positively expressed the desire for less frequent dosing, such as that obtained through LAI formulations. In this work, a comprehensive analysis of marketed LAIs across therapeutic classes and technologies is conducted. The analysis demonstrated an increasing number of new LAIs being brought to the market, recently most as aqueous suspensions and one as a solution, but many other technology platforms were applied as well, in particular, polymeric microspheres and in situ forming gels. The analysis across the technologies provided an insight into to the physicochemical properties the compounds had per technology class as well as knowledge of the excipients typically used within the individual formulation technology. The principle behind the formulation technologies was discussed with respect to the release mechanism, manufacturing approaches, and the possibility of defining predictive in vitro release methods to obtain in vitro in vivo correlations with an industrial angle. The gaps in the field are still numerous, including better systematic formulation and manufacturing investigations to get a better understanding of potential innovations, but also development of new polymers could facilitate the development of additional compounds. The biggest and most important gaps, however, seem to be the development of predictive in vitro dissolution methods utilizing pharmacopoeia described equipment to enable their use for product development and later in the product cycle for quality-based purposes.

Long acting injectable formulations: the state of the arts and challenges of poly(lactic-co-glycolic acid) microsphere, hydrogel, organogel and liquid crystal

Long-acting injectable formulation technologies: challenges and opportunities for the delivery of fragile molecules

An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics

Patient-Centric Long-Acting Injectable and Implantable Platforms─An Industrial Perspective

Injectable long-acting formulations (ILAFs) and manufacturing techniques

Ultra-Long-Term Delivery of Hydrophilic Drugs Using Injectable In Situ Cross-Linked Depots

PLGA/PLA-Based Long-Acting Injectable Depot Microspheres in Clinical Use: Production and Characterization Overview for Protein/Peptide Delivery

Challenges and Complications of Poly(lactic-co-glycolic acid)-Based Long-Acting Drug Product Development

Biocompatible, Injectable Anionic Hydrogels Based on Poly(Oligo Ethylene Glycol Monoacrylate‐co‐Acrylic Acid) for Protein Delivery

Injectable controlled release depots for large molecules

Development and Applications of PLGA Hydrogels for Sustained Delivery of Therapeutic Agents

Clinical translation of long-acting drug delivery formulations

Lyotropic liquid crystals for parenteral drug delivery

Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas

Recent progress in hydrophobic ion-pairing and lipid-based drug delivery systems for enhanced oral delivery of biopharmaceuticals

Preparation and Evaluation of a Phospholipid-Based Injectable Gel for the Long Term Delivery of Leuprolide Acetaterrh.

Recent studies on modulating hyaluronic acid-based hydrogels for controlled drug delivery

Development and Evaluation of a Water-Free In Situ Depot Gel Formulation for Long-Acting and Stable Delivery of Peptide Drug ACTY116

Polyacrylic acid-based drug delivery systems: A comprehensive review on the state-of-art

A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives

The Advances in Phospholipids-Based Phase Separation Gels for the Sustained Release of Peptides, Proteins, and Chemotherapeutics